1. Targeted therapy in melanoma
Ragini R. Kudchadkar, MD, Keiran S.M. Smalley, PhD, L. Frank Glass, MD, James S. Trimble, MD, Vernon K. Sondak, MD 
Clinics in Dermatology 
Volume 31, Issue 2, Pages (March 2013)
DOI: /j.clindermatol
Copyright © 2013 Elsevier Inc. Terms and Conditions

2. Fig. 1
Dramatic reduction in size of multiple subcutaneous nodules seen after 15 weeks of vemurafenib treatment in a patient with BRAF mutant melanoma refractory to standard therapy. (Reprinted with permission from Wagle N et al.52)
Clinics in Dermatology  , DOI: ( /j.clindermatol )
Copyright © 2013 Elsevier Inc. Terms and Conditions

3. Fig. 2
Reduction in size of multiple dermal and subcutaneous nodules seen after 5 months of treatment with dabrafenib and trametinib in a patient with BRAF mutant melanoma refractory to six previous treatments including ipilimumab. The patient had not received prior vemurafenib. (Courtesy of Dr. Jeffrey Infante.)
Clinics in Dermatology  , DOI: ( /j.clindermatol )
Copyright © 2013 Elsevier Inc. Terms and Conditions

4. Fig. 3
Cystic facial skin lesions in a patient treated with vemurafenib.
Clinics in Dermatology  , DOI: ( /j.clindermatol )
Copyright © 2013 Elsevier Inc. Terms and Conditions

5. Fig. 4
Biopsy of one of the skin lesions from the patient shown in Figure 3 reveals dilated infundibula with follicular hyperplasia and hyperkeratosis (hematoxylin & eosin, original magnification ×50).
Clinics in Dermatology  , DOI: ( /j.clindermatol )
Copyright © 2013 Elsevier Inc. Terms and Conditions

6. Fig. 5 Keratosis pilaris in a patient treated with vemurafenib.
Clinics in Dermatology  , DOI: ( /j.clindermatol )
Copyright © 2013 Elsevier Inc. Terms and Conditions